Compare OBK & MLTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OBK | MLTX |
|---|---|---|
| Founded | 1912 | 2021 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 972.7M |
| IPO Year | 2018 | N/A |
| Metric | OBK | MLTX |
|---|---|---|
| Price | $39.36 | $13.95 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 8 | 9 |
| Target Price | ★ $43.00 | $36.33 |
| AVG Volume (30 Days) | 138.4K | ★ 2.0M |
| Earning Date | 01-21-2026 | 11-05-2025 |
| Dividend Yield | ★ 1.53% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.91 | N/A |
| Revenue | ★ $325,588,000.00 | N/A |
| Revenue This Year | $13.94 | N/A |
| Revenue Next Year | $6.04 | N/A |
| P/E Ratio | $20.49 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $28.80 | $5.95 |
| 52 Week High | $41.17 | $62.75 |
| Indicator | OBK | MLTX |
|---|---|---|
| Relative Strength Index (RSI) | 75.67 | 49.37 |
| Support Level | $38.51 | $13.87 |
| Resistance Level | $39.41 | $14.98 |
| Average True Range (ATR) | 0.83 | 0.88 |
| MACD | 0.20 | 0.16 |
| Stochastic Oscillator | 92.17 | 49.59 |
Origin Bancorp Inc is a financial holding company. The bank provides a broad range of financial services to businesses, municipalities, high-net-worth individuals, and retail clients. The bank principally operates in one business segment, community banking. The bank is engaged in attracting deposits from individuals and businesses and using these deposits and borrowed funds to originate commercial, residential mortgage, construction, and consumer loans. The bank generates the majority of its revenue from interest earned on loans and investments, service charges, and fees on deposit accounts.
MoonLake Immunotherapeutics is a clinical-stage biotechnology company advancing therapies to address unmet needs in inflammatory skin and joint diseases. The company is focused on the development of SLK, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody that has the potential, based on response levels seen in clinical trials, to drive disease modification in dermatology and rheumatology patients.